Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
Status:
Completed
Trial end date:
2017-03-29
Target enrollment:
Participant gender:
Summary
The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in
participants with advanced or metastatic gynaecological cancers by disease control rate
(complete response (CR) or partial response (PR) or stable disease (SD) for at least 12
weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1.